Treats elevated intraocular pressure. ANDA 212639, held by Alembic. Dorzolamide Hydrochloride.
As of Nov 21, 2026, ANDA 212639 (Dorzolamide Hydrochloride), held by Alembic, was first approved by FDA on Aug 9, 2019, with 0 approved supplements and 0 published complete response letters.
Dorzolamide hydrochloride ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Dorzolamide hydrochloride ophthalmic solution is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 9, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dorzolamide HydrochlorideEQ 2% BASE · solution/drops;ophthalmic | Dorzolamide Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters